Annual General Meeting 2026

Annual General Meeting FY 2024/25

Invitation to the Annual General Meeting on 11 March 2026 (PDF)

The online portal for the annual general meeting will be available starting February 2, 2026.

ITEM 1:

Submission of the adopted separate annual financial statements and of the approved consolidated financial statements of BRAIN Biotech AG for the fiscal year ending 30 September 2025, the separate management report and the Group management report for the fiscal year from 1 October 2024 until 30 September 2025 with the explanatory reports relating to disclosures pursuant to Sections 289a and 315a of the German Commercial Code (HGB), as well as the report by the Supervisory Board for the fiscal year from 1 October 2024 to 30 September 2025.

Annual Report 2024/25 (PDF)

Group Management Report and Consolidated Financial Statements (Extract from Annual Report 2024/25) (PDF)

HGB Lagebericht und Einzelabschluss der BRAIN Biotech AG 2024/25 - (PDF, German language)

Explanatory report of the management board pursuant to Sections 289a and 315a of the German Commercial Code (HGB) for the financial year 2024/25 (PDF)

ITEM 2:

Resolution concerning the ratification of the actions of the Management Board for the fiscal year from 1 October 2024 to 30 September 2025

The Management and Supervisory boards propose that the actions of the Management Board members holding office during the fiscal year from 1 October 2024 to 30 September 2025 be ratified for this period.

ITEM 3:

Resolution concerning the ratification of the actions of the Supervisory Board for the fiscal year from 1 October 2024 to 30 September 2025

The Management and Supervisory boards propose that the actions of the Supervisory Board members holding office during the fiscal year from 1 October 2024 to 30 September 2025 be ratified for this period.

ITEM 4:

Election of the auditor of the separate financial statements and of the auditor of the consolidated financial statements for the fiscal year from 1 October 2025 to 30 September 2026

Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing Baker Tilly GmbH & Co. KG Wirtschaftsprüfungsgesellschaft to be the auditor of both the separate financial statements and the consolidated financial statements for the fiscal year from 1 October 2025 to 30 September 2026.

Item 4 in full wording (PDF)

ITEM 5:

Elections to the Supervisory Board

Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing Dr. Ursula La Cognata, Berlin, Managing Partner, ybe – Your Biotech Experts Partnerschaftsgesellschaft as a member of the Company’s Supervisory Board with effect as of the conclusion of the AGM on 11 March 2026 until the end of the AGM that ratifies the actions of the Supervisory Board for the fiscal year from 1 October 2028 to 30 September 2029.

Item 5 in full wording (PDF)

Vita Dr Ursula La Cognata (PDF)

ITEM 6:

Resolution concerning the approval of the Compensation Report

The Management and Supervisory boards propose that the Compensation Report for the 2024/25 fiscal year, prepared and audited in accordance with Section 162 AktG, be approved.

Item 6 in full wording (PDF)

Compensation report 2025 (PDF, German language)